bit.bio is unlocking the therapeutic potential of human cells to create a new era of medicine where living medicines are programmed cure chronic and deadly diseases. Through their Identity Cell Codling Platform, the company has developed a way to reprogram stem cells rapidly and at the scale to create novel therapies. bit.bio has developed their Discovery Platform using big data and machine learning to read the code script of each cell. Once the script has been defined, their Opti-ox precision reprogramming technology uses CRISPR and other cell editing techniques to write information into the cell’s genetic code. bit.bio’s Identity Cell Coding Platform is incredibly precise, takes just days, and cuts manufacturing costs to one-tenth of current cell therapies. It’s also scalable, allowing bit.bio to create trillions of cells in a GMP facility, making cell therapy accessible to millions of patients.